Effect of cellular senescence on the growth of HER2-positive breast cancers

Journal of the National Cancer Institute

Volumn 107, Issue 5, 2015, Pages

  Zacarias Fluck, Mariano F ^a   Morancho, Beatriz ^a   Vicario, Rocio ^a   Luque Garcia, Antonio ^a   Escorihuela, Marta ^a   Villanueva, Josep ^a   Rubio, Isabel T ^a   Arribas, Joaquín ^a,b,c  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 6; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER SIZE; CELL AGING; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SENESCENCE; TRANSGENIC MOUSE; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CHEMISTRY; CONFOCAL MICROSCOPY; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; TUMOR CELL LINE; UPREGULATION; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; INTERLEUKIN-6; MICE; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84930037960     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv020     Document Type: Article

References (34)

1. Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. Nature. 2005;436(7051):642-642.
2. Coppé J-PJ, Patil CKC, Rodier FF, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6(12):2853-2868.
3. Kuilman T, Peeper DS. Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer. 2009;9(2):81-94.
4. Narita M, Young ARJ, Arakawa S, et al. Spatial coupling of mTOR and autophagy augments secretory phenotypes. Science. 2011;332(6032):966-970.
5. Chanarat S, Seizl M, Strasser K. Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev. 2011;25(12):1245-1261.
6. Angelini PD, Zacarias Fluck MF, Pedersen K, et al. Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence. Cancer Res. 2013;73(1):450-458.
7. Acosta JC, O'Loghlen A, Banito A, et al. Chemokine Signaling via the CXCR2 Receptor Reinforces Senescence. Cell. 2008;133(6):1006-1018.
8. Kuilman T, Michaloglou C, Vredeveld LCW, et al. Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network. Cell. 2008;133(6):1019-1031.
9. Lujambio A, Akkari L, Simon J, et al. Non-cell-autonomous tumor suppression by p53. Cell. 2013;153(2):449-460.
10. Kang T-W, Yevsa T, Woller N, et al. Senescence surveillance of pre-malignanthepatocytes limits liver cancer development. Nature. 2012;479(7374):547-551.
11. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007;445(7128):661-665.
12. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445(7128):656-660.
13. Gradishar WJ. HER2 therapy-an abundance of riches. N Engl J Med. 2012;366(2):176-178.
14. Ginestier C, Liu S, Diebel ME, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest. 2010;120(2):485-497.
15. Korkaya H, Kim G-I, Davis A, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell. 2012;47(4):570-584.
16. Hartman ZC, Yang X-Y, Glass O, et al. HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. Cancer Res. 2011;71(13):4380-4391.
17. Huang W, Reinholz M, Weidler J, et al. Comparison of Central HER2 Testing With Quantitative Total HER2 Expression and HER2 Homodimer Measurements Using a Novel Proximity-Based Assay. Am J Clin Pathol. 2010;134(2):303-311.
18. Sperinde J, Jin X, Banerjee J, et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res. 2010;16(16):4226-4235.
19. Parra-Palau JL, Pedersen K, Peg V, et al. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers. Cancer Res. 2010;70(21):8537-8546.
20. Pedersen K, Angelini PD, Laos S, et al. A naturally occurring HER2 carboxyterminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol. 2009;29(12):3319-3331.
21. Trost TM, Lausch EU, Fees SA, et al. Premature senescence is a primary failsafe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells. Cancer Res. 2005;65(3):840-849.
22. Burgess A, Vigneron S, Brioudes E, et al. Loss of human Greatwall results in G2 arrest and multiple mitotic defects because of deregulation of the cyclin B-Cdc2/PP2A balance. Proc Natl Acad Sci USA. 2010;107(28):12564-12569.
23. Parra-Palau JL, Morancho B, Peg V, et al. Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. J Natl Cancer Inst. 2014;106(11): In press.
24. Campeau E, Ruhl VE, Rodier F, et al. A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells. PLoS ONE. 2009;4(8):e6529.
25. Reddy JP, Peddibhotla S, Bu W, et al. Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation. Proc Natl Acad Sci USA. 2010;107(8):3728-3733.
26. Du ZZ, Podsypanina KK, Huang SS, et al. Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models. Proc Natl Acad Sci USA. 2006;103(46):17396-17401.
27. d'Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer. 2008;8(7):512-522.
28. Chang Q, Daly L, Bromberg J. Seminars in Immunology. Semin Immunol. 2014;26(1):48-53.
29. Morancho B, Parra-Palau JL, Ibrahim YH, et al. A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers. Oncogene. 2013;32(11):1452-1459.
30. Gorgoulis VG, Halazonetis TD. Oncogene-induced senescence: The bright and dark side of the response. Curr Opin Cell Biol. 2010;22(6):12-12.
31. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. Dosedependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol. 2007;9(5):493-505.
32. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 2010:51-57.
33. Toso A, Revandkar A, Di Mitri D, et al. Enhancing Chemotherapy Efficacy in Pten-Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity. Cell Rep. 2014;9(1):75-89.
34. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol. 1975;66(1):188-193.